[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autologous-hematopoietic-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autologous-hematopoietic-stem-cell-transplantation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100635423","clinical-study-on-the-preservation-of-ovarian-function-following-autologous-hematopoietic-stem-cell-transplantation-using-goserelin-100635423",false,"NCT07552493","Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin","Inclusion Criteria:\n\n1\\. Haematological patients scheduled for autologous haematopoietic stem cell transplantation; 2. Female patients aged 14 to 50 years with regular menstrual cycles prior to transplantation; 3. Patients or their legal representatives must voluntarily participate and sign an informed consent form, demonstrating comprehension and willingness to comply with all study procedures and requirements; 4. Estimated survival exceeding one year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n1\\. Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may compromise study outcomes or increase patient risk; 2. Patients with a history of allergy to goserelin or related medications; 3. Patients who have previously undergone menopause due to physiological or pathological factors; 4. Patients with a history of gynaecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; 5. Patients currently participating in other clinical studies that may influence menstrual recovery; 6. Patients who refuse to participate in this clinical study.","FEMALE","14 Years","50 Years",{"count":19,"type":20},64,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female hematologic patients aged 14 to 50 years scheduled for autologous hematopoietic stem cell transplantation (auto-HSCT). Participants will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group. The conditioning regimen for autologous hematopoietic stem cell transplantation primarily employs melphalan. A melphalan dose \\>140 mg\u002Fm² constitutes myeloablative conditioning (MAC), while a dose ≤140 mg\u002Fm² is classified as non-myeloablative conditioning. Within each group, patients were randomly assigned 1:1 to the experimental group (goserelin prophylaxis) or control group using a random number table. The experimental group received a single 3.6mg subcutaneous injection of goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group did not receive goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplantation (defined as ≥3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs). Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; Other reproductive parameters: ovarian and uterine volume, endometrial thickness; time to neutrophil\u002Fplatelet engraftment; disease recurrence rate; transplant-related mortality; and adverse event (AE) incidence. This study aims to evaluate the efficacy of goserelin in improving ovarian function following autologous hematopoietic stem cell transplantation in hematologic malignancy patients.",[26,27],"Ovarian Insufficiency","Autologous Hematopoietic Stem Cell Transplantation",[29,30],"Autologous haematopoietic stem cell transplantation","Ovarian insufficiency","NOT_YET_RECRUITING","2026-04-20",{"date":34,"type":35},"2026-04-27","ACTUAL",{"date":37,"type":20},"2026-05-01",{"date":39,"type":20},"2027-10-01",{"name":41,"class":42},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",5,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100579024","hetrombopag-in-promoting-platelet-engraftment-after-auto-hsct-in-children-with-neuroblastoma-100579024","NCT06818916","Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma","Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma","Inclusion Criteria:\n\n* Age\\\u003C18 years old;\n* Diagnosed as neuroblastoma;\n* ECOG ≤ 2;\n* First time receiving autologous hematopoietic stem cell transplantation;\n* The subjects or their legal guardians agree to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* ALT\u002FAST \\> 3 ULN, or TBIL \\> 1.5 ULN;\n* Have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment;\n* Suffering from thromboembolic diseases;\n* Other situations that are not suitable for inclusion in the study determined by researchers.","ALL","18 Years",{"count":54,"type":20},30,[23],"The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is:\n\n· Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \\> 100\\*10\\^9\u002FL.",[58,59,27],"Delayed Platelet Engraftment","Neuroblastoma",[61,62,63,64,65],"Hetrombopag","delayed platelet engraftment","neuroblastoma","pediatrics","autologous hematopoietic stem cell transplantation","RECRUITING","2025-11-26",{"date":69,"type":35},"2025-12-03",{"date":71,"type":35},"2024-06-30",{"date":73,"type":20},"2027-07-31",{"name":75,"class":42},"Beijing Children's Hospital",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":76},"100491613","clinical-study-of-improved-beam-conditioning-regimen-for-asct-in-lymphoma-100491613","NCT05681403","Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma","Clinical Study of Mitoxantrone Hydrochloride Liposome, Carmostine, Etoposide and Cytarabine as Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Lymphoma","Inclusion Criteria:\n\n* Subjects volunteered to join the study, signed informed consent, had good compliance, and cooperated with follow-up.\n* Aged 18-60 years, male or female.\n* Subjects pathologically diagnosed non-Hodgkin's lymphoma, and intend to undergo autologous hematopoietic stem cell transplantation.\n* ECOG score 0-1.\n* Meet the following requirements: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times the upper limit of normal value (ULN), total bilirubin (TBIL) ≤1.5×ULN (AST and ALT≤5×ULN are allowed if liver invasion occurs); serum creatinine ≤1.5×ULN; international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5×ULN; ECG examination was normal or abnormal without clinical significance, cardiac ultrasound showed left ventricular ejection fraction (LVEF) greater than 60, or CK-MB is normal, pro-BNP less than 900 pg\u002FmL.\n* Female subjects have negative serum pregnancy test result. Subjects use highly effective birth control methods throughout the trial.\n\nExclusion Criteria:\n\n* Previous recipients of mitoxantrone or mitoxantrone liposome; previous treatment with doxorubicin or other anthracyclines, with a cumulative dose of doxorubicin \\> 360 mg\u002Fm2 (for other anthracyclines, 1 mg doxorubicin is equivalent to 2 mg epirubicin).\n* Hypersensitivity to any study drug or its component.\n* Uncontrolled systemic diseases (e.g., active infections, uncontrolled hypertension, diabetes, etc.) .\n* Cardiac function and disease meet one of the following conditions: a) Long QTc syndrome or QTc interval \\>480 ms; b) Complete left bundle branch block, degree II or III atrioventricular block; c) Severe uncontrolled arrhythmias that require medical treatment; d) New York College of Cardiology Grade ≥ III; e) Cardiac ejection fraction (LVEF) less than 60%; f) A history of myocardial infarction, unstable angina pectoris, severely unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities within 6 months prior to recruitment.\n* Active hepatitis B and C infection (positive HBV sAg and HBV-DNA more than 1x10\\^3 copies\u002FmL; HCV-RNA more than 1x10\\^3 copies\u002FmL) .\n* Positive HIV antibody.\n* Previous or current co-occurrence of other malignancies (except for effectively controlled non-melanoma basal cell carcinoma of the skin, breast\u002Fcervical carcinoma in situ, and other malignancies that have been effectively controlled without treatment in the past 5 years) .\n* Primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at the time of recruitment.\n* Pregnant or lactating female subjects and those who do not want to take contraceptive measures.\n* Drug abuse (non-medical use of narcotic drugs or psychotropic drugs) or drug dependence (sedative hypnotics, analgesics, anesthetics, excitants and psychotropic drugs, etc.).\n* A history of mental disease or cognitive impairment.\n* Other conditions that the investigator determined are not suitable for participation in the study.","60 Years",{"count":86,"type":20},53,[23],"This is a single arm, open, single-center clinical study. The patients who are diagnosed with lymphoma and intend to undergo ASCT will be enrolled. The aim of this study is to investigate the efficacy and safety of the conditioning regimen using mitoxantrone hydrochloride liposome, BCNU, etoposide and cytarabine for ASCT.",[90,27],"Lymphoma","2022-12-26",{"date":93,"type":35},"2023-01-12",{"date":95,"type":20},"2023-01-15",{"date":97,"type":20},"2026-12-31",{"name":99,"class":42},"First Affiliated Hospital Xi'an Jiaotong University"]